The Cluster Randomised Trial of PSA Testing for Prostate Cancer (CAP) [30], the European Randomised Study of Screening for Prostate Cancer (ERSPC) [31,32] and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) [33] were three large randomised prospective trials that assessed the value of PSA screening in asymptomatic men for PC diagnosis. The gene discussed is KLK3; the disease is ovarian cancer.